Cargando…
Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival
BACKGROUND: Cancer cachexia is a catabolic condition characterized by skeletal muscle wasting, consequent to tumor burden, which negatively impacts tolerance to cancer therapies and contributes to increased mortality. Partly because of the limited knowledge of the underlying mechanisms of cancer cac...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322478/ https://www.ncbi.nlm.nih.gov/pubmed/30637373 http://dx.doi.org/10.1093/jncics/pky043 |
_version_ | 1783385613630701568 |
---|---|
author | Judge, Sarah M Nosacka, Rachel L Delitto, Daniel Gerber, Michael H Cameron, Miles E Trevino, Jose G Judge, Andrew R |
author_facet | Judge, Sarah M Nosacka, Rachel L Delitto, Daniel Gerber, Michael H Cameron, Miles E Trevino, Jose G Judge, Andrew R |
author_sort | Judge, Sarah M |
collection | PubMed |
description | BACKGROUND: Cancer cachexia is a catabolic condition characterized by skeletal muscle wasting, consequent to tumor burden, which negatively impacts tolerance to cancer therapies and contributes to increased mortality. Partly because of the limited knowledge of the underlying mechanisms of cancer cachexia derived from human studies, however, the ability to therapeutically intervene remains elusive. The purpose of the current study was therefore to better define the phenotype of skeletal muscle obtained from patients with pancreatic ductal adenocarcinoma (PDAC), which has one of the highest rates of cachexia. METHODS: Morphological analyses were performed on rectus abdominis muscle biopsies obtained from resectable PDAC patients undergoing tumor resection surgery (N = 20) and from weight-stable non-cancer control subjects undergoing benign abdominal surgery (N = 16). PDAC patients with a body weight loss of greater than 5% during the previous 6 months were considered cachectic (N = 15). Statistical tests were two sided. RESULTS: Skeletal muscle from cachectic PDAC patients had increased collagen content compared with non-cancer control subjects (1.43% vs 9.66%, P = .0004, Dunn test). Across all PDAC patients, collagen content positively correlated with body weight loss (P = .0016, r = 0.672), was increased in patients with lymph node metastasis (P = .007, Mann-Whitney U test), and was associated with survival on univariate (HR = 1.08, 95% confidence interval [CI] = 1.02 to 1.04, P = .008) and multivariable analyses (HR = 1.08, 95% CI = 1.00 to 1.17, P = .038). Cachectic PDAC patients also displayed increased lipid deposition (2.63% vs 5.72%, P = .042), infiltration of CD68+ macrophages (63.6 cells/mm(2) vs 233.8 cells/mm(2), P = .0238), calcium deposition (0.21% vs 2.51%, P = .030), and evidence of deficient cellular quality control mechanisms (Mann-Whitney U test). Transcriptional profiling of all patients supported these findings by identifying gene clusters related to wounding, inflammation, and cellular response to TGF-β upregulated in cachectic PDAC patients compared with non-cancer control subjects. CONCLUSIONS: To our knowledge, this work is the first to demonstrate increased collagen content in cachectic PDAC patients that is associated with poor survival. |
format | Online Article Text |
id | pubmed-6322478 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63224782019-01-10 Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival Judge, Sarah M Nosacka, Rachel L Delitto, Daniel Gerber, Michael H Cameron, Miles E Trevino, Jose G Judge, Andrew R JNCI Cancer Spectr Article BACKGROUND: Cancer cachexia is a catabolic condition characterized by skeletal muscle wasting, consequent to tumor burden, which negatively impacts tolerance to cancer therapies and contributes to increased mortality. Partly because of the limited knowledge of the underlying mechanisms of cancer cachexia derived from human studies, however, the ability to therapeutically intervene remains elusive. The purpose of the current study was therefore to better define the phenotype of skeletal muscle obtained from patients with pancreatic ductal adenocarcinoma (PDAC), which has one of the highest rates of cachexia. METHODS: Morphological analyses were performed on rectus abdominis muscle biopsies obtained from resectable PDAC patients undergoing tumor resection surgery (N = 20) and from weight-stable non-cancer control subjects undergoing benign abdominal surgery (N = 16). PDAC patients with a body weight loss of greater than 5% during the previous 6 months were considered cachectic (N = 15). Statistical tests were two sided. RESULTS: Skeletal muscle from cachectic PDAC patients had increased collagen content compared with non-cancer control subjects (1.43% vs 9.66%, P = .0004, Dunn test). Across all PDAC patients, collagen content positively correlated with body weight loss (P = .0016, r = 0.672), was increased in patients with lymph node metastasis (P = .007, Mann-Whitney U test), and was associated with survival on univariate (HR = 1.08, 95% confidence interval [CI] = 1.02 to 1.04, P = .008) and multivariable analyses (HR = 1.08, 95% CI = 1.00 to 1.17, P = .038). Cachectic PDAC patients also displayed increased lipid deposition (2.63% vs 5.72%, P = .042), infiltration of CD68+ macrophages (63.6 cells/mm(2) vs 233.8 cells/mm(2), P = .0238), calcium deposition (0.21% vs 2.51%, P = .030), and evidence of deficient cellular quality control mechanisms (Mann-Whitney U test). Transcriptional profiling of all patients supported these findings by identifying gene clusters related to wounding, inflammation, and cellular response to TGF-β upregulated in cachectic PDAC patients compared with non-cancer control subjects. CONCLUSIONS: To our knowledge, this work is the first to demonstrate increased collagen content in cachectic PDAC patients that is associated with poor survival. Oxford University Press 2019-01-07 /pmc/articles/PMC6322478/ /pubmed/30637373 http://dx.doi.org/10.1093/jncics/pky043 Text en © The Author(s) 2019. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Article Judge, Sarah M Nosacka, Rachel L Delitto, Daniel Gerber, Michael H Cameron, Miles E Trevino, Jose G Judge, Andrew R Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival |
title | Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival |
title_full | Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival |
title_fullStr | Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival |
title_full_unstemmed | Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival |
title_short | Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival |
title_sort | skeletal muscle fibrosis in pancreatic cancer patients with respect to survival |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322478/ https://www.ncbi.nlm.nih.gov/pubmed/30637373 http://dx.doi.org/10.1093/jncics/pky043 |
work_keys_str_mv | AT judgesarahm skeletalmusclefibrosisinpancreaticcancerpatientswithrespecttosurvival AT nosackarachell skeletalmusclefibrosisinpancreaticcancerpatientswithrespecttosurvival AT delittodaniel skeletalmusclefibrosisinpancreaticcancerpatientswithrespecttosurvival AT gerbermichaelh skeletalmusclefibrosisinpancreaticcancerpatientswithrespecttosurvival AT cameronmilese skeletalmusclefibrosisinpancreaticcancerpatientswithrespecttosurvival AT trevinojoseg skeletalmusclefibrosisinpancreaticcancerpatientswithrespecttosurvival AT judgeandrewr skeletalmusclefibrosisinpancreaticcancerpatientswithrespecttosurvival |